CSS
IMVT icon

Cubist Systematic Strategies’s Immunovant IMVT Stock Holding History

Cubist Systematic Strategies’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,800
Closed -$268K – 3144
2024
Q4 		$268K Hold
10,800
– – ﹤0.01% 2452
2024
Q3 		$308K Hold
10,800
– – ﹤0.01% 2414
2024
Q2 		$285K Sell
10,800
-5,000
-32% -$142K ﹤0.01% 2378
2024
Q1 		$510K Hold
15,800
– – ﹤0.01% 2591
2023
Q4 		$666K Buy
+15,800
New +$581K ﹤0.01% 2356

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Cubist Systematic Strategies's IMVT Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Immunovant (IMVT) stake by 168% in Q3 2025, buying an estimated $2.56M and bringing the position to 252,712 shares worth $4.07M. The position accounts for 0.02% of the portfolio, ranked #1087.

Cubist Systematic Strategies first reported a position in IMVT in Q1 2020 and has held it in 18 quarters since. The position peaked at $7.07M in Q3 2023. 186 funds tracked by Wall St. Rank hold IMVT as of Q3 2025.

  • Cubist Systematic Strategies held 252,712 shares of Immunovant worth $4.07M as of Q3 2025.
  • Cubist Systematic Strategies bought 158,425 Immunovant shares in Q3 2025, an estimated $2.56M.
  • Immunovant made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1087 holding.
  • Cubist Systematic Strategies first reported a position in Immunovant in Q1 2020 and has held it in 18 quarters since.
  • Cubist Systematic Strategies's Immunovant position peaked at $7.07M in Q3 2023.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.